Teleflex awarded Short Term Central Venous Catheters contract from Vizient
Including market leading Arrow™ CVCs and Arterial CathetersWAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a...
Antimicrobial
Chungnam National University Researchers Develop A Rapid Water Quality Monitoring Chip for Antibiotic Detection
DAEJEON, South Korea, Dec. 20, 2024 /PRNewswire/ -- Antimicrobial resistance (AMR) is a growing global health crisis because of microbes,...
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases
Appointment of seasoned executives with substantial industry expertise strengthens team as the company advances programs into the clinicCAMBRIDGE, Mass., Dec....
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
Milestone demonstrates the growing customer adoption of the Company’s proprietary technologyLEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems,...
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from...
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing...
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the...
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne --...
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a...
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue streamLEXINGTON, Mass., Dec....
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial...
Avails Medical announces the commencement of U.S. Pilot Trial for the eAST™ system
MENLO PARK, Calif., Dec. 3, 2024 /PRNewswire/ -- Avails Medical, Inc., a leader in rapid, automated, and fully electrical antibiotic susceptibility...
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
- STAR-1 topline results expected in March 2025 -- Over 30 million acne patients seek treatment in the U.S. each...
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026,...
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare GlobalWINNIPEG, Manitoba, Nov. 27, 2024...
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives
SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic...
Teva Takes on Antimicrobial Resistance (AMR): What You Need to Know
NORTHAMPTON, MA / ACCESSWIRE / November 20, 2024 / Antimicrobial resistance (AMR) happens when bacteria no longer respond to antibiotics,...
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
Additions of ProgenaMatrix® and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolioPOMPANO BEACH, Fla., Nov....
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders’ Equity Up 8.8% to $35M
Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.Solid liquidity position, with cash...